If you have been reading about 胃饥饿素受体 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-12. Numbers and descriptions here follow the published literature rather than marketing material.
Ipamorelin 是一种合成五肽，在 20 世纪 90 年代被报道为生长激素促分泌剂。其结构基于胃饥饿素受体激动剂的设计思路，但并非天然激素。早期药理学研究显示，它可刺激垂体释放生长激素，而对应激激素轴的影响相对较小。该化合物常被用作研究生长激素调节通路的工具分子。
在机制层面，ipamorelin 与生长激素促分泌受体 1a 型结合，该受体也介导胃饥饿素的多种效应。受体激活后，细胞内信号促进生长激素从垂体前叶释放。由于对促肾上腺皮质激素和皮质醇的刺激较弱，它被视为选择性较高的促分泌剂。这种选择性在动物模型和少量人体研究中被观察到，但人体数据仍然有限。
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
| Property | Value | Notes |
|---|---|---|
| 分子式 | C38H49N9O5 | 五肽，含非天然氨基酸残基 |
| 分子量 | 711.85 g/mol | 理论值，盐形式可能略有差异 |
| 外观 | 白色至类白色粉末 | 冻干粉常见 |
| 溶解性 | 易溶于水 | 也可溶于部分极性有机溶剂 |
| 储存条件 | -20°C，干燥避光 | 长期保存通常推荐 |
Identity and purity assessment for a research peptide of this kind typically combines reversed-phase high-performance liquid chromatography with mass spectrometry. The chromatographic run separates related impurities and yields a purity percentage, while electrospray ionization or matrix-assisted laser desorption mass spectrometry confirms the expected molecular mass. Amino acid analysis or tandem mass spectrometry sequencing can add confidence when material is intended for quantitative work. Laboratories differ in how they calculate and report purity, so figures from different sources are not always directly comparable.
Lyophilized material is generally stored cold and dry, with desiccant, and protected from light. In solution the peptide is more vulnerable: the histidine side chain can oxidize, and repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. A mildly acidic aqueous buffer is often used for short-term handling because it limits several degradation routes. Accurate prediction of long-term stability under a given set of conditions is difficult, and published stability data remain sparse.
Published discussion of this compound is uneven. Some references describe it as a tool for probing growth hormone regulation, while others focus on analytical characterization or on comparisons with related secretagogues. Statements about selectivity, half-life and potency often trace back to a small number of original reports that later authors cite secondhand. Readers evaluating a claim should therefore check whether a figure reflects a direct measurement or a repeated citation, and whether the underlying study was conducted in animals, in isolated cells or in human volunteers.
Reversed-phase high-performance liquid chromatography is the standard tool for assessing purity. Detection near 214 nanometers captures the peptide backbone, and the resulting chromatogram shows the main peak alongside related impurities. Electrospray ionization mass spectrometry confirms molecular mass and supports sequence verification. Common degradation products include oxidized residues, deamidated forms, and truncated fragments, each appearing as a distinct peak or shoulder in the trace.
Quality claims for research peptides vary widely across suppliers. A certificate of analysis should list purity by chromatography, the mass found by spectrometry, and the analytical conditions used. Independent testing at a third-party laboratory is a common way to check identity and purity, because documents alone cannot confirm what is inside a vial. Purity figures describe the proportion of the target peptide among detected species, and they say nothing about biological activity or sterility.
Lyophilized ipamorelin powder is the form usually supplied for laboratory work. Kept dry, protected from light, and held at minus 20 degrees Celsius or below, it remains stable for extended periods, often measured in years. Once dissolved, the peptide degrades faster through hydrolysis, oxidation, and deamidation, so solutions are typically refrigerated and used within weeks. Repeated freeze-thaw cycles and exposure to alkaline conditions accelerate loss of the parent compound.
J Obstet Gynaecol Can. 40 (7): 931–934. doi:10.1016/j.jogc.2018.01.004. PMID 29921430. Lamb YN (September 2018). "Elagolix: First Global Approval". Drugs. 78 (14): 1501–1508. doi:10.1007/s40265-018-0977-4. PMC 6244606. PMID 30194661. Vercellini P, Viganò P, Barbara G, Buggio L, Somigliana E (February 2019). "Elagolix for endometriosis: all that glitters is not gold". Hum. Reprod. 34 (2): 193–199. doi:10.1093/humrep/dey368. PMID 30551159. Barra F, Scala C, Ferrero S (April 2019). "Elagolix sodium for the treatment of women with moderate to severe endometriosis-associated pain". Drugs Today. 55 (4): 237–246. doi:10.1358/dot.2019.55.4.2930713. PMID 31050692. S2CID 143434963.
A) Airway - Assess and protect airway and potentially the cervical spine B) Breathing - Maintain adequate ventilation and oxygenation C) Circulation - Assess for and control bleeding to maintain organ perfusion including focused assessment with sonography for trauma (FAST) D) Disability - Perform basic neurological exam including Glasgow Coma Scale (GCS) E) Exposure - Expose entire body and search for any missed injuries, entry points, and exit points while maintaining body temperature Depending on the extent of injury, management can range from urgent surgical intervention to observation. As such, any history from the scene such as gun type, shots fired, shot direction and distance, blood loss on scene, and pre-hospital vitals signs can be very helpful in directing management. Unstable people with signs of bleeding that cannot be controlled during the initial evaluation require immediate surgical exploration in the operating room. Otherwise, management protocols are generally dictated by anatomic entry point and anticipated trajectory.
== Further reading == DOE Fundamentals Handbook: Nuclear Physics and Reactor Theory Volume 1 (PDF). U.S. Department of Energy. January 1993. DOE-HDBK-1019/1-93. Archived from the original (PDF) on 2014-03-19. Retrieved 2012-01-03. DOE Fundamentals Handbook: Nuclear Physics and Reactor Theory Volume 2 (PDF). U.S. Department of Energy. January 1993. DOE-HDBK-1019/2-93. Archived from the original (PDF) on 2013-12-03. Retrieved 2012-01-03. Bulgac, Aurel; Jin, Shi; Stetcu, Ionel (2020). "Nuclear Fission Dynamics: Past, Present, Needs, and Future". Frontiers in Physics. 8 63. arXiv:1912.00287. Bibcode:2020FrP.....8...63B. doi:10.3389/fphy.2020.00063.
==== Monoamine oxidase B (MAO-B) inhibitors ==== Rasagiline (Agilect; AGN-1135; Azilect; Elbrus; Lu-00-773; TV-1030; TVP-101; TVP-1012) – monoamine oxidase B (MAO-B) inhibitor [338] Safinamide (EMD-1195686; Equfina; FCE-26743; ME-2125; NW-1015; Onstryv; PNU-151774; Xadago; ZP-034) – reversible monoamine oxidase B (MAO-B) inhibitor and other actions [339] Selegiline (Eldepryl, Jumex) – monoamine oxidase B (MAO-B) inhibitor and other actions Selegiline orally disintegrating tablet (Efupi; FPF-1100-NW; selegiline ODT) – monoamine oxidase B (MAO-B) inhibitor and other actions [340]
Sources: en.wikipedia.org
In March 1907 several of Eddy's relatives filed an unsuccessful lawsuit, the "Next Friends suit," against members of Eddy's household, alleging that she was unable to manage her own affairs. Calvin Frye, her long-time personal assistant, was a particular target of the allegations. The New York World's front-page story in October 1906, headline "Mrs. Mary Baker G. Eddy Dying; Footman and Dummy Control Her," said that Eddy was housebound and dying of cancer, that her staff had taken control of her fortune, and that another woman was impersonating her in public. The newspaper persuaded Eddy's family (or "next friends") to file a lawsuit. Several joined the action, including Eddy's biological son, George Glover, and adoptive son, Ebenezer J. Foster Eddy. Eddy was interviewed in her home in August 1907 by the judge and two psychiatrists, who concluded that she was mentally competent. In response to the McClure's and New York World stories, Eddy asked the church in July 1908 to found the Christian Science Monitor as a platform for responsible journalism. It appeared in November that year, with the motto "To injure no man, but to bless all mankind," and went on to win seven Pulitzer Prizes between 1950 and 2002. Eddy died two years later, on the evening of Saturday, December 3, 1910, aged 89. The Mother Church announced at the end of the Sunday morning service that Eddy had "passed from our sight." It said that "the time will come when there will be no more death," but that Christian Scientists "do not look for [Mrs.
==== Subepidermal calcified nodule ==== Subepidermal calcified nodule is characterized by calcification of the skin resulting from the deposition of calcium and phosphorus, occurring most frequently as one or a few skin lesions on the scalp or face of children.
== Treatment == Treatment for myositis depends on the underlying cause. For myositis, which is caused by a viral infection, no treatment is typically needed. For myositis caused by a bacterial infection, antibiotics can be used. For myositis caused by a medication, it is important to stop using that medication. There are a variety of treatment options available if myositis is caused by an autoimmune disease. Glucocorticoids are often the first choice for treatment. This drug works to weaken the immune system so that it is not able to attack the muscles. It is a type of steroid and can cause a wide array of side effects, such as mood changes, increased hunger, trouble sleeping, etc. Another treatment option is a steroid-sparing immunosuppressive agent. This also works to weaken the immune system but does not cause the side effects that steroids do. Another treatment option is a class of drugs called biologics. Also, intravenous immunoglobulins (IVIg) have been shown to be effective in the treatment of myositis caused by an autoimmune disease.
Sources: en.wikipedia.org
=== Type III civilization methods === Type III civilizations might use the same techniques as a Type II civilization, but applied individually to all possible stars in one or more galaxies. They may also be able to tap into the energy released by the supermassive black holes believed to exist at the center of most galaxies. White holes could theoretically provide large amounts of energy by collecting the matter ejected outward. Capturing the energy of gamma-ray bursts is another theoretically possible power source for an advanced civilization. The emissions from quasars are comparable to those from small active galaxies and could be a massive power source if they could be collected.
== Acneiform eruptions == Acneiform eruptions are caused by changes in the pilosebaceous unit. Acne aestivalis (Mallorca acne) Acne conglobata Acne cosmetica (cosmetic acne) Acne fulminans (acute febrile ulcerative acne) Acne keloidalis nuchae (acne keloidalis, dermatitis papillaris capillitii, folliculitis keloidalis, folliculitis keloidis nuchae, nuchal keloid acne) Acne mechanica Acne medicamentosa Acne miliaris necrotica (acne varioliformis) Acne vulgaris (acne simplex) Acne with facial edema (solid facial edema) Blepharophyma Chloracne Erythrotelangiectatic rosacea (erythematotelangiectatic rosacea, vascular rosacea) Excoriated acne (acne excoriée des jeunes filles, Picker's acne) Glandular rosacea Gnathophyma Gram-negative rosacea Granulomatous facial dermatitis Granulomatous perioral dermatitis Halogen acne Hidradenitis suppurativa (acne inversa, pyoderma fistulans significa, Verneuil's disease) Idiopathic facial aseptic granuloma Infantile acne Lupoid rosacea (granulomatous rosacea, micropapular tuberculid, rosacea-like tuberculid of Lewandowsky) Lupus miliaris disseminatus faciei Metophyma Neonatal acne (acne infantum, acne neonatorum, neonatal cephalic pustulosis) Occupational acne Oil acne Ocular rosacea (ophthalmic rosacea, ophthalmorosacea) Otophyma Periorificial dermatitis Persistent edema of rosacea (chronic upper facial erythematous edema, Morbihan's disease, rosaceous lymphedema) Phymatous rosacea Pomade acne Papulopustular rosacea (inflammatory rosacea) Perifolliculitis capitis abscedens et suffodiens (dissecting cellulitis of the scalp, dissecting folliculitis, perifolliculitis capitis abscedens et suffodiens of Hoffman) Perioral dermatitis Periorbital dermatitis (periocular dermatitis) Pyoderma faciale (rosacea fulminans) Rhinophyma Rosacea (acne rosacea) Rosacea conglobata Synovitis–acne–pustulosis–hyperostosis–osteomyelitis syndrome (SAPHO syndrome) Steroid rosacea Tar acne Tropical acne
It was initially primarily consumed by the elite, with expensive cocoa supplied by colonial plantations in the Americas. In the 18th century, it was considered southern European, aristocratic and Catholic, and was still produced in a similar way to the way it had been produced by the Aztecs. Starting in the 18th century, chocolate production was improved. In the 19th century, engine-powered milling was developed. In 1828, Coenraad Johannes van Houten patented a hydraulic press that separated cocoa butter from chocolate liquor, enabling the mass production of defatted cocoa powder and creating the foundation for the modern solid chocolate industry. Other developments in the 19th century, including the melanger (a mixing machine), modern milk chocolate, the conching process to make chocolate smoother and change the flavor meant a worker in 1890 could produce fifty times more chocolate with the same labor than they could before the Industrial Revolution, and chocolate became a food to be eaten rather than drunk. As production moved from the Americas to Asia and Africa, mass markets in Western nations for chocolate opened up. In the early 20th century, British chocolate producers including Cadbury and Fry's faced controversy over the labor conditions in the Portuguese cacao industry in Africa. A 1908 report by a Cadbury agent described conditions as "de facto slavery." While conditions somewhat improved with a boycott by chocolate makers, slave labor among African cacao growers again gained public attention in the early 21st century.
Many of the former Varian employees now honor Russell Varian's legacy of innovation by funding the Varian Young Investigator Award that recognizes early career investigators in NMR that make significant advancements in instrument development.
Sources: en.wikipedia.org
不是。它属于人工合成的五肽，设计上模拟胃饥饿素受体的部分作用，但不存在于人体天然激素谱中。
生长激素释放激素通过其专用受体起作用，而 ipamorelin 主要作用于胃饥饿素受体。两者可影响生长激素释放，但信号通路和下游效应并不相同。
研究多集中在生长激素释放的急性调节、受体选择性以及不同给药方式下的药代动力学。临床终点研究数量有限，长期结局尚不明确。
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.